Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Federal Trade Commission
Chubb
Mallinckrodt
Novartis
Cantor Fitzgerald
Daiichi Sankyo
Fuji
McKinsey
US Army

Generated: October 23, 2017

DrugPatentWatch Database Preview

VERELAN Drug Profile

« Back to Dashboard

Which patents cover Verelan, and when can generic versions of Verelan launch?

Verelan is a drug marketed by Recro Gainesville and is included in two NDAs.

The generic ingredient in VERELAN is verapamil hydrochloride. There are sixteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

Summary for Tradename: VERELAN

US Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list5
Bulk Api Vendors: see list40
Clinical Trials: see list8
Patent Applications: see list2,213
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VERELAN at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-001May 29, 1990ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-003Nov 25, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-004May 10, 1996RXYesYes► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-003Jan 9, 1992ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-002May 29, 1990ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-002Nov 25, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-001Nov 25, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VERELAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-001May 29, 1990► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-002May 29, 1990► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-003Jan 9, 1992► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-004May 10, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VERELAN

Drugname Dosage Strength RLD Submissiondate
verapamil hydrochlorideExtended-release Tablets100 mg and 200 mgVerelan PM7/20/2006
verapamil hydrochlorideExtended-release Tablets300 mgVerelan PM5/19/2006
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School
Medtronic
Novartis
Argus Health
Citi
Daiichi Sankyo
Accenture
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot